Literature DB >> 25270140

Endoscopic supraorbital eyebrow approach for the surgical treatment of extraaxialand intraaxial tumors.

Roberto Gazzeri1, Yuya Nishiyama, Charles Teo.   

Abstract

OBJECT: The supraorbital eyebrow approach is a minimally invasive technique that offers wide access to the anterior skull base region and parasellar area through asubfrontal corridor. The use of neuroendoscopy allows one to extend the approach further to the pituitary fossa, the anterior third ventricle, the interpeduncular cistern, the anterior and medial temporal lobe, and the middle fossa. The supraorbital approach involves a limited skin incision, with minimal soft-tissue dissection and a small craniotomy, thus carrying relatively low approach-related morbidity.
METHODS: All consecutive patients who underwent the endoscopic supraorbital eyebrow approach were retrospectively analyzed for lesion location, pathology, length of stay, complications, and cosmetic results.
RESULTS: During a 56-month period, 97 patients (mean age 58.5 years) underwent an endoscopic eyebrow approach to resect extra- and intraaxial brain lesions. The most common pathologies treated were meningiomas (n = 41); craniopharyngiomas (n = 22); dermoid tumors (n = 7); metastases (n = 4); gliomas (n = 3); and other miscellaneous frontal, parasellar, and midbrain (n = 23) lesions. The median length of postoperative hospital stay was 2.7 days (range 1-8 days). In 82 patients a total removal of the lesion was performed, while in 15 patients a near-total or subtotal removal was achieved. There were no postoperative hematomas, cerebrospinal fluid leaks, or severe neurological deficits, with the exception of 2 cases of visual deterioration and 1 case each of meningitis, stroke, and third cranial nerve paresis. Other complications directly related to the approach included 2 cases of skin burn as a direct result of heat transmission from the microscope light, 1 case of right frontal palsy, 2 cases of frontal numbness, and 1 case of bone remodeling 1 year after surgery.
CONCLUSIONS: The endoscopic supraorbital eyebrow approach is a safe and effective minimally invasive approach to remove extra- and intraaxial anterior skull base, parasellar, and frontal lesions, promoting a rapid recovery and short hospital stay. The location of the eyebrow incision demands a meticulous cosmetic closure, but, with proper technique, cosmetic results are excellent.

Entities:  

Keywords:  DNET = dysembryoplastic neuroepithelial tumor; VASC = visual analog scale for cosmesis; brain tumor; craniopharyngioma; endoscopy; eyebrow approach; meningioma; subfrontal craniotomy; supraorbital approach

Mesh:

Year:  2014        PMID: 25270140     DOI: 10.3171/2014.7.FOCUS14203

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  5 in total

1.  Minimally Invasive Approaches to Anterior Skull Base Meningiomas.

Authors:  Scott C Seaman; Muhammad S Ali; Anthony Marincovich; Luyuan Li; Jarrett E Walsh; Jeremy D W Greenlee
Journal:  J Neurol Surg B Skull Base       Date:  2020-12-29

2.  Endoscope-controlled extended supraorbital keyhole approach through a modified eyebrow incision for a large dural-based solitary fibrous tumor of the frontal convexity: A technical note.

Authors:  Waleed Azab; Mustafa Najibullah; Ghada Waheed
Journal:  Surg Neurol Int       Date:  2022-04-15

Review 3.  The expanding role of the endonasal endoscopic approach in pituitary and skull base surgery: A 2014 perspective.

Authors:  Bjorn Lobo; Annie Heng; Garni Barkhoudarian; Chester F Griffiths; Daniel F Kelly
Journal:  Surg Neurol Int       Date:  2015-05-20

4.  Supraorbital Craniotomy for Large Anterior Skull Base Meningiomas: A Technical Note.

Authors:  Kiran Khanapure; Krishna Chaitanya Joshi; Aniruddha T Jagannatha; Parichay J Perikal; Syed Aezaz Quryshi; Umesh Srikantha; Ravi Gopal Verma; Alankar S Hegde
Journal:  Asian J Neurosurg       Date:  2019 Jul-Sep

Review 5.  Intracranial Metastatic Disease: Present Challenges, Future Opportunities.

Authors:  Alyssa Y Li; Karolina Gaebe; Katarzyna J Jerzak; Parneet K Cheema; Arjun Sahgal; Sunit Das
Journal:  Front Oncol       Date:  2022-03-07       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.